Identification of clinically relevant protein targets in prostate cancer with 2D-DIGE coupled mass spectrometry and systems biology network platform

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Ummanni, Ramesh ^a   Mundt, Frederike ^a   Pospisil, Heike ^b   Venz, Simone ^c   Scharf, Christian ^c   Barett, Christine ^a   Fälth, Maria ^d   Köllermann, Jens ^a   Walther, Reinhard ^c   Schlomm, Thorsten ^a   Sauter, Guido ^a   Bokemeyer, Carsten ^a   Sültmann, Holger ^d   Schuppert, A ^e   Brümmendorf, Tim H ^a,e   Balabanov, Stefan ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b TECHNICAL UNIVERSITY OF APPLIED SCIENCES WILDAU   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ACTIN; ALBUMIN; BIOLOGICAL MARKER; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; CRYSTALLIN; DIMETHYLARGININASE; ELONGATION FACTOR 1; ELONGATION FACTOR 1GAMMA; GLUCONOLACTONASE; GLUCOSE REGULATED PROTEIN; GLUTATHIONE TRANSFERASE P1; INITIATION FACTOR 4A; INORGANIC PYROPHOSPHATASE; LAMBDA CRYSTALLIN; PROTEASOME; PROTEIN DISULFIDE ISOMERASE; PROTEIN SERINE THREONINE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RIBOSOME PROTEIN; TRANSALDOLASE; UNCLASSIFIED DRUG; TRANSCRIPTOME; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRINCIPAL COMPONENT ANALYSIS; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; SYSTEMS BIOLOGY; TWO DIMENSIONAL GEL ELECTROPHORESIS; CLUSTER ANALYSIS; CYTOLOGY; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

CLUSTER ANALYSIS; HUMANS; MALE; NEOPLASM PROTEINS; PRINCIPAL COMPONENT ANALYSIS; PROSTATE; PROSTATIC NEOPLASMS; PROTEOMICS; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SYSTEMS BIOLOGY; TANDEM MASS SPECTROMETRY; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 79951844814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016833     Document Type: Article

References (46)

1. Landis SH, Murray T, Bolden S, Wingo PA, (1999) Cancer statistics, 1999. CA Cancer J Clin 49: 8-31, 1.
2. Scardino PT, (1989) Early detection of prostate cancer. Urol Clin North Am 16: 635-655.
3. Breslow N, Chan CW, Dhom G, Drury RA, Franks LM, et al. (1977) Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 20: 680-688.
4. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
5. Bjellqvist B, Ek K, Righetti PG, Gianazza E, Gorg A, et al. (1982) Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications. J Biochem Biophys Methods 6: 317-339.
6. O'Farrell PH, (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250: 4007-4021.
7. Alessandro R, Belluco C, Kohn EC, (2005) Proteomic approaches in colon cancer: promising tools for new cancer markers and drug target discovery. Clin Colorectal Cancer 4: 396-402.
8. Lexander H, Palmberg C, Auer G, Hellstrom M, Franzen B, et al. (2005) Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 27: 263-272.
9. Meehan KL, Holland JW, Dawkins HJ, (2002) Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50: 54-63.
10. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, et al. (2000) Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21: 2235-2242.
11. Ummanni R, Junker H, Zimmermann U, Venz S, Teller S, et al. (2008) Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer. Cancer Lett 266: 171-185.
12. Lin JF, Xu J, Tian HY, Gao X, Chen QX, et al. (2007) Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer 121: 2596-2605.
13. Marouga R, David S, Hawkins E, (2005) The development of the DIGE system: 2D fluorescence difference gel analysis technology. Anal Bioanal Chem 382: 669-678.
14. Gleason DF, Mellinger GT, (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111: 58-64.
15. Mellinger GT, Gleason D, Bailar J III, (1967) The histology and prognosis of prostatic cancer. J Urol 97: 331-337.
16. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
17. Lukk M, Kapushesky M, Nikkila J, Parkinson H, Goncalves A, et al. (2010) A global map of human gene expression. Nat Biotechnol 28: 322-324.
18. Jeong H, Mason SP, Barabasi AL, Oltvai ZN, (2001) Lethality and centrality in protein networks. Nature 411: 41-42.
19. Hessels D, Verhaegh GW, Schalken JA, Witjes JA, (2004) Applicability of biomarkers in the early diagnosis of prostate cancer. Expert Rev Mol Diagn 4: 513-526.
20. Kumar-Sinha C, Rhodes DR, Yu J, Chinnaiyan AM, (2003) Prostate cancer biomarkers: a current perspective. Expert Rev Mol Diagn 3: 459-470.
21. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, et al. (2002) alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287: 1662-1670.
22. Solassol J, Marin P, Demettre E, Rouanet P, Bockaert J, et al. (2005) Proteomic detection of prostate-specific antigen using a serum fractionation procedure: potential implication for new low-abundance cancer biomarkers detection. Anal Biochem 338: 26-31.
23. Killian CS, Emrich LJ, Vargas FP, Yang N, Wang MC, et al. (1986) Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst 76: 179-185.
24. Pang J, Liu WP, Liu XP, Li LY, Fang YQ, et al. (2010) Profiling protein markers associated with lymph node metastasis in prostate cancer by DIGE-based proteomics analysis. J Proteome Res 9: 216-226.
25. Eschrich S, Zhang H, Zhao H, Boulware D, Lee JH, et al. (2009) Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys 75: 497-505.
26. Balk SP, Knudsen KE, (2008) AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6: e001.
27. Heinlein CA, Chang C, (2004) Androgen receptor in prostate cancer. Endocr Rev 25: 276-308.
28. Gao X, Porter AT, Honn KV, (1997) Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. Adv Exp Med Biol 407: 41-53.
29. Sciavolino PJ, Bate-Shen C, (1998) Molecular biology of prostate development and prostate cancer. Ann Med 30: 357-368.
30. Nagy B, Szendroi A, Romics I, (2009) Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy. Pathol Oncol Res 15: 279-283.
31. Chan CC, Dostie J, Diem MD, Feng W, Mann M, et al. (2004) eIF4A3 is a novel component of the exon junction complex. RNA 10: 200-209.
32. Lee S, Baek M, Yang H, Bang YJ, Kim WH, et al. (2002) Identification of genes differentially expressed between gastric cancers and normal gastric mucosa with cDNA microarrays. Cancer Lett 184: 197-206.
33. Rotondo R, Mastracci L, Piazza T, Barisione G, Fabbi M, Cassanello M, et al. (2008) Arginase 2 is expressed by human lung cancer, but it neither induces immune suppression, nor affects disease progression. Int J Cancer 123: 1108-1116.
34. Tabib A, Bachrach U, (1999) Role of polyamines in mediating malignant transformation and oncogene expression. Int J Biochem Cell Biol 31: 1289-1295.
35. Russell DH, (1981) Polyamines and prostatic function. Prog Clin Biol Res 75A: 207-224.
36. Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, et al. (2008) Expression of arginase II in prostate cancer. Int J Oncol 32: 357-365.
37. Mumenthaler SM, Rozengurt N, Livesay JC, Sabaghian A, Cederbaum SD, et al. (2008) Disruption of arginase II alters prostate tumor formation in TRAMP mice. Prostate 68: 1561-1569.
38. Immenschuh S, Baumgart-Vogt E, (2005) Peroxiredoxins, oxidative stress, and cell proliferation. Antioxid Redox Signal 7: 768-777.
39. Imlay JA, Linn S, (1988) DNA damage and oxygen radical toxicity. Science 240: 1302-1309.
40. Ames BN, Gold LS, Willett WC, (1995) The causes and prevention of cancer. Proc Natl Acad Sci U S A 92: 5258-5265.
41. Cerutti PA, (1994) Oxy-radicals and cancer. Lancet 344: 862-863.
42. Kim H, Lee TH, Park ES, Suh JM, Park SJ, et al. (2000) Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem 275: 18266-18270.
43. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y, (2003) Peroxiredoxins in breast carcinoma. Clin Cancer Res 9: 3418-3424.
44. Galigniana MD, Harrell JM, O'Hagen HM, Ljungman M, Pratt WB, (2004) Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem 279: 22483-22489.
45. Cheung-Flynn J, Prapapanich V, Cox MB, Riggs DL, Suarez-Quian C, et al. (2005) Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol 19: 1654-1666.
46. Cronauer MV, Ince Y, Engers R, Rinnab L, Weidemann W, et al. (2007) Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression. Oncogene 26: 1875-1884.